Adaptive Biotechnologies (ADPT)
Provides clonoSEQ residual-disease testing and immune-receptor discovery services.
Something off on this page? Send us feedback.
Sells clonoSEQ testing to clinicians and drug developers for detecting measurable residual disease in lymphoid cancers, while licensing immune-receptor data and discovery tools through Immune Medicine. U.S. reimbursement underpins the diagnostics business, and management is pursuing a separation of Immune Medicine.
Uses next-generation immune-receptor sequencing to detect and monitor measurable residual disease in lymphoid cancers. The MRD business sells clonoSEQ clinical testing to hematologists and applies the same assay in biopharmaceutical trials, where results can serve as drug-development endpoints. FDA authorization, Medicare and private-payor coverage, and integration with oncology records support adoption in the United States; access abroad remains limited and reimbursement less developed.
Immune Medicine turns T- and B-cell receptor data into immunosequencing services, licensed datasets, prediction models, and target-discovery work for research and drug-development partners. Its platform combines sequencing with computational biology to map receptors to disease-linked antigens. Management is evaluating ways to separate Immune Medicine and has designated MRD diagnostics as the post-separation focus.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | National Bank | Target | Target: — | Target: $34 |
| Sep 21, 2026 | BTIG | Target | Target: $25 | Target: $34 |
| Aug 4, 2026 | Piper Sandler | Reiterate | Rating: —Target: $21 | Target: $27.50 |
| Jul 30, 2026 | Guggenheim | Reiterate | Rating: —Target: $22 | Target: $25 |
| Jul 30, 2026 | BTIG | Reiterate | Rating: —Target: $22 | Target: $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $344.3M · Total debt $410.5M · Total assets $640.7M · Shareholders' equity $142.9M
- Revenue
- $71.6M
- Operating income
- −$15.8M
- Net income
- −$39.8M
No dividends on record.
| Institutions | 98.38% | 157.00M shares | |
|---|---|---|---|
| 309 holders · as of Jun 30, 2026 | |||
| Insiders | 1.64% | 2.61M shares | |
| 11 holders · as of Sep 18, 2026 | |||
| Adds to | 100.02% | ||
159.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 100.02%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Viking Global Investors LPInstitution | 18.79% | 29.99M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.49% | 15.14M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.01% | 6.40M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 3.70% | 5.91M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 3.43% | 5.48M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Francis Lo | officer: Chief People Officer | −115,406 | $28.06 |
| Sep 15, 2026 | Susan Bobulsky | officer: Chief Commercial Officer, MRD | −1,195 | $27.00 |
| Aug 26, 2026 | Katey Einterz Owen | director | −9,615 | $26.00 |
| Aug 18, 2026 | Robert Hershberg | director | −30,664 | $24.40 |
| Aug 18, 2026 | Chad M. Robins | director, officer: CEO and Chairman | −278,676 | $24.48 |
- Natera
Personalized ctDNA MRD platform across solid tumors
- Guardant Health
Tissue-free ctDNA MRD and monitoring alternative
- 10x Genomics
Single-cell immune profiling research-tools rival
- Tempus AI
AI-enabled oncology data and monitoring platform
- Personalis
Ultra-sensitive tumor-informed MRD testing peer
- NeoGenomics
Oncology lab competitor and clonoSEQ channel partner
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies | $27.93 | −0.48% | $4.49B | — | — | 14.6 | +21.5% |
| Natera | $392.16 | +0.32% | $55.98B | — | — | 20.7 | +37.7% |
| Guardant Health | $178.03 | +0.49% | $23.77B | — | — | 20.1 | +44.3% |
| 10x Genomics | $76.84 | −4.78% | $10.25B | — | — | 16.6 | −12.7% |
| Tempus AI | $76.80 | −0.51% | $13.52B | — | — | 9.4 | +21.6% |
| Personalis | $16.15 | −1.31% | $1.75B | — | — | 25.1 | +30.0% |
| NeoGenomics | $18.63 | −1.40% | $485.4M | — | 67.0 | 0.6 | +11.2% |
| Median | — | 67.0 | 18.4 | +25.8% |